Table 2.
Baseline characteristics for participating cohorts in the 2-y baseline period analysis
| eGFR < 60 | eGFR ≥60 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | Age | % Female |
% Black |
Baseline eGFR |
Total Chol |
SBP | % DM |
% CVD |
% Alb |
% Smoke |
Age | % Female |
% Black |
Baseline eGFR |
Total Chol |
SBP | % DM |
% CVD |
% Alb |
% Smoke |
| AASK | 54 (11) | 39 | 100 | 42 (11) | 5 (1) | 150 (24) | 0 | 53 | 64 | 44 | 55 (10) | 38 | 100 | 67 (6) | 5 (1) | 150 (24) | 0 | 45 | 38 | 41 |
| ADVANCE | 69 (6) | 54 | 0 | 51 (8) | 5 (1) | 147 (23) | 100 | 31 | 39 | 9 | 66 (6) | 40 | 0 | 83 (13) | 5 (1) | 144 (21) | 100 | 24 | 28 | 16 |
| Aichi | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 49 (6) | 18 | 0 | 92 (14) | 5 (1) | 126 (15) | 0.3 | 0.06 | 4.2 | 31 |
| AKDN | 73 (11) | 60 | 0 | 48 (10) | n/a | n/a | 18 | 17 | 12 | n/a | 54 (15) | 59 | 0 | 89 (16) | n/a | n/a | 7 | 4 | 4 | n/a |
| BC CKD | 70 (13) | 46 | 0 | 33 (10) | 5 (1) | 134 (22) | 42 | 4 | 69 | 6 | 56 (15) | 45 | 1 | 78 (16) | 5 (2) | 136 (23) | 52 | 1 | 67 | 6 |
| CARE | 66 (7) | 21 | 2 | 52 (7) | 5 (0) | 134 (20) | 18 | 100 | 19 | 8 | 58 (9) | 12 | 3 | 80 (13) | 5 (0) | 128 (18) | 13 | 100 | 11 | 17 |
| CCF | 72 (11) | 55 | 12 | 47 (10) | 5 (1) | 131 (19) | 26 | 22 | 27 | 8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| CIRCS | 63 (6) | 70 | 0 | 54 (6) | 5 (1) | 135 (19) | 6 | 4 | 7 | 14 | 54 (9) | 66 | 0 | 84 (12) | 5 (1) | 130 (17) | 5 | 1 | 2 | 23 |
| CRIB | 61 (15) | 34 | 6 | 28 (9) | 6 (1) | 150 (23) | 16 | 44 | 81 | 12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Framingham | 70 (6) | 52 | 0 | 51 (8) | 5 (1) | 139 (16) | 20 | 13 | n/a | 13 | 59 (9) | 50 | 0 | 89 (18) | 5 (1) | 127 (18) | 9 | 5 | 12 | 15 |
| Geisinger | 70 (10) | 59 | 1 | 52 (8) | 5 (1) | 131 (19) | 31 | 15 | 44 | 7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| GLOMMS 1 | 70 (13) | 50 | 0 | 33 (7) | n/a | n/a | 61 | 48 | 72 | 11 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| IPHS | 70 (6) | 68 | 0 | 54 (6) | 5 (1) | 139 (17) | 9 | 16 | 9 | 9 | 59 (10) | 68 | 0 | 87 (12) | 5 (1) | 133 (18) | 5 | 5 | 2 | 7 |
| KP Hawaii | 71 (11) | 53 | 0 | 47 (10) | 5 (1) | 137 (22) | 52 | 35 | 66 | 7 | 58 (13) | 49 | 0 | 86 (16) | 5 (1) | 135 (20) | 67 | 16 | 41 | 13 |
| KPNW | 71 (10) | 48 | 2 | 47 (11) | n/a | 142 (23) | 40 | 24 | 8 | 13 | 67 (10) | 55 | 5 | 73 (10) | n/a | 142 (22) | 46 | 20 | 11 | 11 |
| KSHS | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 37 (7) | 34 | 0 | 91 (11) | 5 (1) | 114 (14) | 2 | 1 | 1 | 30 |
| Maccabi | 72 (11) | 58 | 0 | 50 (9) | 5 (1) | 134 (19) | 30 | 9 | 40 | 1 | 47 (15) | 59 | 0 | 94 (19) | 5 (1) | 124 (17) | 11 | 1 | 17 | 2 |
| MASTERPLAN | 61 (12) | 31 | 0 | 36 (11) | 5 (1) | 136 (20) | 24 | 30 | 37 | 21 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MDRD | 52 (12) | 38 | 7 | 35 (11) | 6 (1) | 132 (18) | 4 | 13 | 83 | 10 | 47 (12) | 63 | 11 | 65 (4) | 6 (1) | 129 (20) | 7 | 7 | n/a | n/a |
| MRFIT | 52 (5) | 0 | 5 | 55 (5) | 6 (1) | 130 (17) | 10 | 3 | 13 | 34 | 47 (6) | 0 | 7 | 89 (13) | 6 (1) | 128 (14) | 5 | 1 | 3 | 58 |
| NephroTest | 60 (14) | 32 | 10 | 37 (12) | 5 (1) | 137 (20) | 24 | 19 | 96 | 15 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| NZDCS | 71 (9) | 57 | 0 | 48 (10) | 5 (1) | 142 (21) | 100 | 2 | 14 | 8 | 59 (13) | 49 | 0 | 86 (16) | 5 (1) | 138 (19) | 100 | 1 | 7 | 16 |
| Ohasama | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 63 (8) | 67 | 0 | 84 (11) | 5 (1) | 129 (17) | 8 | 2 | 5 | 16 |
| Pima | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 32 (14) | 63 | 0 | 122 (15) | 4 (1) | 118 (17) | 27 | n/a | 18 | 28 |
| PREVEND | 67 (9) | 53 | 0 | 53 (7) | 5 (1) | 137 (21) | 16 | 16 | 27 | 22 | 52 (11) | 49 | 1 | 83 (13) | 5 (1) | 125 (18) | 8 | 5 | 8 | 32 |
| Rancho Bernardo | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 69 (5) | 52 | 0 | 78 (11) | 5 (1) | 132 (17) | 16 | 10 | 8 | 8 |
| RENAAL | 61 (7) | 38 | 13 | 40 (11) | 6 (1) | 152 (19) | 100 | 44 | 100 | 18 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Severance | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 44 (9) | 38 | 0 | 90 (15) | 5 (1) | 120 (18) | 1 | 0.4 | 4 | 32 |
| Sunnybrook | 69 (14) | 40 | 0 | 38 (12) | n/a | n/a | 37 | 48 | 81 | 5 | 52 (16) | 46 | 0 | 91 (20) | n/a | n/a | 26 | 23 | 79 | 5 |
| Taiwan | 63 (10) | 40 | 0 | 52 (8) | 5 (1) | 139 (24) | 9 | 9 | 12 | 21 | 40 (12) | 50 | 0 | 96 (15) | 5 (1) | 119 (18) | 2 | 2 | 1 | 22 |
| VA CKD | 75 (9) | 3 | 8 | 48 (9) | 4 (1) | n/a | 43 | 45 | 41 | n/a | 69 (10) | 3 | 11 | 71 (13) | 4 (1) | n/a | 52 | 38 | 72 | n/a |
| ZODIAC | 74 (8) | 72 | 0 | 50 (8) | 6 (1) | 159 (24) | 100 | 43 | 43 | 13 | 64 (11) | 49 | 0 | 77 (12) | 6 (1) | 155 (25) | 100 | 28 | 32 | 23 |
|
| ||||||||||||||||||||
| Total | 74 (10) | 20 | 7 | 48 (10) | 4 (1) | 135 (20) | 38 | 35 | 38 | 6 | 51 (16) | 51 | 1 | 92 (18) | 5 (1) | 125 (18) | 14 | 6 | 17 | 8 |
Mean (SD). n/a: Not available for relevant baseline period but included in other baseline period(s).eGFR: estimated glomerular filtration rate. Chol: cholesterol. SBP: systolic blood pressure. DM: diabetes mellitus. CVD: history of cardiovascular disease. Alb: albuminuria, proportion of participants with urine albumin-to-creatinine ratio ≥30 mg/g or urine protein-to-creatinine ratio ≥50 mg/g or dipstick protein ≥1+. Smoke: current cigarette smoking.
Appendices 1 and 2 provide further information regarding each cohort.